ANASTASIA AMIRAMOVA: Open Payments
NPI 1982327987 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,825 in 110 payments from 15 companies in 2025. Trend: 2023 $2,071 · 2024 $4,056 · 2025 $2,825
Food & beverage: $2,725Education: $100
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $836 |
| ABBVIE INC. | 19 | $413 |
| E.R. Squibb & Sons, L.L.C. | 20 | $319 |
| Axsome Therapeutics, Inc. | 13 | $313 |
| HARMONY BIOSCIENCES LLC | 6 | $238 |
| Luye Pharma (USA) Ltd. | 4 | $198 |
| Alkermes, Inc. | 5 | $175 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
Products named: CAPLYTA, VRAYLAR, COBENFY, Auvelity, ERZOFRI EXTENDED-RELEASE, WAKIX, Qelbree, LYBALVI.
Industry payments across MO — which companies pay providers there.
